Skip to content

Navigating new regulations in biobanking for clinical studies and research projects

View Webinar

Watch Prof. Jonathan Douxfils, CEO and Co-Founder of QUALIblood discuss the:

  • Importance of biobanking in advancing medical research and personalized treatments.
  • Need for regulations to ensure ethical and legal practices in biobanking.
  • Latest regulations impacting biobanking for clinical studies and research projects including their impact on clinical studies, changes researchers may need to implement in their projects and potential challenges in complying with new regulations.

After graduating in pharmaceutical sciences in 2011, Prof. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015. In 2017 he launched QUALIblood, a Contract Research Organization (CRO) aiming to provide industries, hospitals, and universities with central laboratory services for blood investigations. His company employs 7 people actively working on pre-clinical, phase-1, phase-2, and phase-3 clinical trials in several pharmaceutical fields. In 2018, he gained an academic position at the University of Namur in Belgium where he teaches pharmacology to students in bachelor and master’s degrees. He also provides continuing education for health professionals, especially for pharmacists and clinical biologists. In 2019, he received the Eberhard F. Mammen Young Investigator Award for his research on the development of a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes. In 2020, he was nominated as the “Namurois of Year”, category Sciences, a prize rewarding people in the Namur community for their engagement and their scientific discovery. In 2023, he was appointed Professor by the University of Namur.